Q2 · MEDICINE
Article
Author: Mascanfroni, Ivan ; Rothblatt, Jonathan ; Safaee, Helia ; Tong, Zhixiang ; Perrault, Christelle ; Musabeyezu, Juliet ; Massadeh, Salam ; Majid, Tahir ; Alhasan, Ali H ; Quintana, Francisco J ; Kenison, Jessica E ; Milton, Yuka ; Heinelt, Martina ; Wang, Qingping ; Alaamery, Manal ; Karp, Jeffrey M ; De Biasio, Michael ; Siders, William ; Lan, Haoyue ; Kuang, Heidi ; Levy, Oren ; Multon, Marie-Christine ; Rothhammer, Veit ; Yeste, Ada ; Kuai, Rui
Mesenchymal stem cells (MSCs) are promising candidates for the development of cell-based drug delivery systems for autoimmune inflammatory diseases, such as multiple sclerosis (MS). Here, we investigated the effect of Ro-31-8425, an ATP-competitive kinase inhibitor, on the therapeutic properties of MSCs. Upon a simple pretreatment procedure, MSCs spontaneously took up and then gradually released significant amounts of Ro-31-8425. Ro-31-8425 (free or released by MSCs) suppressed the proliferation of CD4+ T cells in vitro following polyclonal and antigen-specific stimulation. Systemic administration of Ro-31-8425-loaded MSCs ameliorated the clinical course of experimental autoimmune encephalomyelitis (EAE), a murine model of MS, displaying a stronger suppressive effect on EAE than control MSCs or free Ro-31-8425. Ro-31-8425-MSC administration resulted in sustained levels of Ro-31-8425 in the serum of EAE mice, modulating immune cell trafficking and the autoimmune response during EAE. Collectively, these results identify MSC-based drug delivery as a potential therapeutic strategy for the treatment of autoimmune diseases. KEY MESSAGES: MSCs can spontaneously take up the ATP-competitive kinase inhibitor Ro-31-8425. Ro-31-8425-loaded MSCs gradually release Ro-31-8425 and exhibit sustained suppression of T cells. Ro-31-8425-loaded MSCs have more sustained serum levels of Ro-31-8425 than free Ro-31-8425. Ro-31-8425-loaded MSCs are more effective than MSCs and free Ro-31-8425 for EAE therapy.